Chronic ITP Treatment receives Orphan Drug Designation
9/8/2015; Posted by: WeBleed staff
Rigel Pharmaceuticals recently announced that the US Food and Drug Administration (FDA) had granted Orphan Drug designation to its Fostamatinib.
The FDA grants Orphan Drug status to medications that are in development for treating, diagnosing, or preventing rare disorders that affect fewer than 200,000 people living in the United States.
“Receiving this Orphan Drug designation from the FDA is a positive step forward in the development of Fostamatinib,” said Raul Rodriguez, president and chief executive officer of Rigel. “We look forward to completing our Phase 3 program and intend to file a New Drug Application for Fostamatinib in ITP in the U.S.,” he added.
Fostamatinib is an oral medication and is believed to combat the autoimmune nature of ITP by blocking IgG receptor signals to stop antibodies from destroying platelets. To learn more about Fostamatinib and how it works within the body, please watch the video below.
webleed.org – your source for bleeding news!
Photo/Video credit: Rigel Pharmaceuticals
